Their data indicate that T cell responses to TAAs were comparable to viral antigen-specific responses and, therefore, suggest that the HLA-E immunopeptidome can be exploited for CD8+ T cell-based immunotherapies against cancer. The gene discussed is CD8A; the disease is cancer.